Meridian Health System

Synthetic marijuana reduces agitation in patients with Alzheimer’s

A Phase II study found dronabinol significantly reduced behavioral agitation in patients with Alzheimer's disease. The medication also improved caregivers' burden and daily living skills.

SourceMeridian Health System·DateNov 14, 2003

Synthetic marijuana compound reduces agitation, improves appetite in Alzheimer's patients

Dronabinol significantly reduced agitation in 66% of Alzheimer's patients and improved functional status in 69%, while also addressing weight loss. These findings suggest dronabinol as a potential treatment option for managing behavioral symptoms in patients with Alzheimer's disease.

SourceMeridian Health System·DateAug 20, 2003